Blenrep Gets European Nod to Treat Multiple Myeloma
The drug is an antibody drug conjugate comprising a humanized IgG1κ monoclonal antibody targeting the B-cell maturation antigen (BCMA), conjugated with a cytotoxic agent, maleimidocaproyl monomethylauristatin F (mcMMAF). Belantamab mafodotin binds to BCMA on the surface of myeloma cells, causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity. According to the manufacturer, GSK, it is the first such conjugate to be approved and represents a new mechanism of action compared with existing agents.
Generally Poor Prognosis
Multiple myeloma is a rare and incurable disease of the plasma cells, typically affecting adults older than 60 years of age. First-line therapy is usually with targeted cancer drugs such as lenalidomide or bortezomib in combination with a steroid, sometimes with chemotherapy and a stem cell transplant. Relapses are treated similarly. The disease has a generally poor prognosis and there is a need for novel effective therapies. Blenrep had been designated as an orphan medicine, and the EMA will now review the information to determine whether this can be maintained.
CHMP said that two phase 3, randomized, open-label studies had shown that adding Blenrep to standard therapy of either bortezomib and dexamethasone in patients who have received at least one prior therapy, or pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide, prolonged progression-free survival in patients with relapsed or refractory multiple myeloma.
Ocular Side Effects Common
The safety and tolerability profiles of the Blenrep combinations were broadly consistent with those of the individual agents. The most common side effects with Blenrep include reduced visual acuity, corneal examination abnormalities (including keratopathy), thrombocytopenia, blurred vision, dry eye, foreign-body sensation in eyes, eye pain, photophobia, eye irritation, neutropenia, anemia, and diarrhea.
Patients should have an ophthalmic examination, including visual acuity and slit-lamp examination, by an eye care professional before each of the first four doses of Blenrep, and as clinically indicated thereafter. Patients should be encouraged to inform their physicians of any ocular symptoms.
The drug will be available as 70 mg or 100 mg powder for concentrate for solution for infusion. It is administered as a 30-minute infusion every 3 or 4 weeks. Treatment should be prescribed by physicians experienced in the treatment of multiple myeloma.
Detailed recommendations will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NHS ‘invisible waiting list' as three million patients await specialist appointments
Three million patients in England have had no appointment after being referred by their GPs to specialist care, a new analysis has suggested. NHS England figures last month estimated 7.36 million treatments were waiting to be carried out at the end of May, relating to just under 6.23 million patients. The new analysis from MBI Health suggests almost half of those have been left in limbo. Delays in making a first assessment can lead to late diagnosis, worsening symptoms and pressure on emergency services. The Patients Association, which represents patients across the country, said if accurate, the situation was 'staggering' and meant millions are waiting on an 'invisible waiting list.' The analysis comes after data showed the NHS is making progress in reducing the overall waiting list ahead of Sir Keir Starmer's promise for 92 per cent of patients to be treated within 18 weeks by March 2029 - a target not met since 2015. MBI's analysis found that around 70 per cent of referral to treatment pathways fall into the category of being 'unseen' since the patient's GP referred them to a specialist. The latest figures show how challenging that target will be, given an estimated one million of the three million unseen patients have already gone more than 18 weeks without receiving any care. The analysis found that ear, nose and throat (ENT), trauma and orthopaedics, gastroenterology, ophthalmology and gynaecology and obstetrics departments were consistently the specialist departments with the greatest number of patients not seen for the first time. Rachel Power, the chief executive of the Patients Association, told the Guardian 'If accurate, three million people are trapped in an invisible waiting list crisis, stuck without basic diagnostic tests of first appointments while their conditions worsen,' 'The scale is staggering, as nearly half of all patients on a waiting list haven't been seen by anyone. That's not a healthcare service; that's a breakdown. 'These aren't just statistics. They're people checking their phones daily for hospital calls that never come, unable to plan their lives while their symptoms deteriorate.' Last month, figures showed 56.1 per cent of those on the list at the end of June this year were of working age (defined as age 19 to 64), up from 55.8 per cent a year ago and 55 per cent in June 2022. At the same time, the proportion of people on the waiting list under the age of 19 has fallen, standing at 10.8 per cent in June this year, down from 11.2 per cent a year earlier and 11.9 per cent in June 2022. The proportion who are over 65 has remained broadly unchanged at around 33.1 per cent. The Department of Health and Social Care (DHSC) said: 'Thanks to this government's record investment, reforms and the hard work of NHS staff, we've cut the waiting list by over 260,000 since July 2024, which also fell for the first time in 17 years in April and May outside the pandemic. On top of this, we have also delivered 4.6m appointments – more than double the 2m we promised. 'This government is delivering the fundamental reform needed to turn our NHS around, and our 10-year health plan will build on this progress, to ensure we meet our target that 92 per cent of patients wait no longer than 18 weeks for treatment by March 2029.' The DHSC did not comment on the three million unseen patients.
Yahoo
an hour ago
- Yahoo
Essex NHS trust expands award-winning programme to support 'rising stars'
A talent development programme aimed at supporting rising stars in the NHS from minority ethnic backgrounds has been expanded. The Essex Partnership University NHS Foundation Trust (EPUT) launched the Resilience, Intelligence, Strength, and Excellence (RISE) initiative four years ago. This year, the award-winning programme was broadened to include staff across the mid and south Essex Integrated Care System. Paul Taylor, director of organisational development and culture at EPUT, said: "Across the mid and south Essex system, we benefit from having a diverse workforce with an incredible breadth of talent, much of which can go untapped. Read more Shrimpers striker Spasov excited to face his former side in friendly Driver, 88, failed eyesight test after causing death by dangerous driving in Essex "EPUT established the RISE programme to play a vital role in bringing this to light, making space, and elevating that potential." It is aimed at increasing the number of senior leaders from Black and minority ethnic backgrounds. The programme has so far seen 187 participants graduate, including 20 staff members this year alone. EPUT was named Best Employer for Diversity and Inclusion at the Nursing Times Workforce Awards 2024 for RISE.
Yahoo
an hour ago
- Yahoo
I won't ever sit back and declare ‘job done', says drugs minister
Drugs minister Maree Todd has said she will never 'sit back, relax and say 'job done'' in the fight against drug deaths. Ms Todd was appointed to the role in June following the death of Christina McKelvie earlier this year from secondary breast cancer. Despite the circumstances of the appointment, the former mental health pharmacist said she was 'excited' to move from the social care brief to drugs as the Government continues its push to tackle the level of addiction and death across Scotland. The minister inherits a legacy which has been long-criticised by opponents, with Scotland having the highest drug death rates in Europe – a figure which actually increased between 2022 and 2023 in the latest available confirmed data. Just this week, figures showed the number of suspected drug deaths between March and May of this year increased by 15% compared to the previous 13 weeks. Speaking to the PA news agency, the minister said there is a 'consensus' that 'the work we are doing is the right kind of work', but the Government is responding to a 'changing landscape'. When the Government launched its national mission on drugs under the premiership of Nicola Sturgeon, the focus was largely on opioids such as heroin. But that has shifted, reflecting an increase in the injection of cocaine and the spectre of synthetic opioids known as nitazenes. On the latter, the minister said: 'They are unbelievably potent, super-strong, very tiny amounts can cause fatal overdoses easily.' As it looks to deal with the shifting threat posed by drugs, she stressed the need for the Government to be 'agile'. Ms Todd said: 'We've just had our rapid action drug alerts and response (Radar) statistics released this week and we've seen a rise in deaths, a rise in Naloxone use, a rise in hospital admissions. 'We are seeing some absolutely significant and tangible harm occurring because of the change in the drug supply. 'I suppose the lesson that provides to me is that we need to be agile. 'I don't think we do one thing and this job is done and we fixed the problem that Scotland faces, we have to continually look carefully at what's happening in Scotland, understand the challenges that we're facing, understand the harms that people are experiencing.' She added: 'I don't think I would ever sit back and relax and say 'job done'. 'I think we've seen some significant progress, but each of these deaths is an absolute tragedy – it's a family who's lost a loved one, it's a loss of potential and contribution to our communities.' The way forward, she said , is a job for the whole of Government, saying there is a need for 'primary prevention'. The minister said: 'We need to be thinking, why is it that Scotland faces this challenge and what can we do to shift the likelihood that people growing up in Scotland will turn to drugs and alcohol as they grow older?' Earlier this year, the Thistle Centre opened in the east end of Glasgow, a UK-first safe consumption room giving those struggling with addiction a safe place to inject drugs. Since opening, the facility has supervised 3,008 injecting episodes and dealt with 39 medical emergencies, which could include administering Naloxone or even resuscitation. 'People would definitely have died if they had not been in that unit,' Ms Todd said. 'I think in March, there was a cluster of very profound overdose episodes, I think this is the issue with nitazenes, they act very fast, so people were really unwell really quickly and it takes a lot of Naloxone because of its potency.' In other parts of Scotland without the benefit of a safe consumption room where that specific batch of drug was used, the minister said: 'Where people used it, they did die.'
